Citations

Citations to this article as recorded by  

• Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases
  Xuesong Yang, Yan Wu, Anqiang Wang, Xiuli Ma, Kai Zhou, Ke Ji, Xin Ji, Ji Zhang, Xiaojiang Wu, ZhongWu Li, Zhaode Bu
  The Journal of Pathology: Clinical Research.2024;[Epub]     CrossRef
• My battle with cancer. Part 1
  Mikhail V. Blagosklonny
  Oncoscience.2024; 11: 1.     CrossRef
• SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma
  Patricia L. Theard, Amanda J. Linke, Nancy E. Sealover, Brianna R. Daley, Johnny Yang, Katherine Cox, Robert L. Kortum
  Molecular Oncology.2024; 18(3): 641.     CrossRef
• Synthetic approaches and application of representative clinically approved fluorine-enriched anti-cancer medications
  He-Nan Liu, Ying Zhu, Yuan Chi, Fei-Fei Sun, Li-Shen Shan, Ya-Tao Wang, Bing Dai
  European Journal of Medicinal Chemistry.2024; 276: 116722.     CrossRef
• Multifunctional dendrimer-peptide conjugates for MET receptor-specific imaging of cancer cells
  Jin Woong Lee, Kwangok P. Nickel, Rachel L. Minne, Justin J. Jeffery, Eduardo Aluicio-Sarduy, Carter Kim, DaWon Kim, Piper A. Rawding, Michael J. Poellmann, Narsimha Mamidi, Jonathan W. Engle, Jung Heon Lee, Hansoo Park, Reinier Hernandez, Randall J. Kimp
  Nano Today.2024; 59: 102509.     CrossRef
• Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics
  Hafiza Padinharayil, Jinsu Varghese, Mithun Chacko John, Golgodu Krishnamurthy Rajanikant, Cornelia M. Wilson, Minnatallah Al-Yozbaki, Kaviyarasi Renu, Saikat Dewanjee, Rupa Sanyal, Abhijit Dey, Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Abilash Val
  Genes & Diseases.2023; 10(3): 960.     CrossRef
• Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences
  Yuhao Ye, Zhiyu Huang, Maoqing Zhang, Jiayue Li, Yiqiong Zhang, Chenghua Lou
  Biomedicine & Pharmacotherapy.2023; 159: 114183.     CrossRef
• Quinolines: Privileged Scaffolds for Developing New Anti‐neurodegenerative Agents
  M.Sc.Shivani Chauhan, Tarana Umar, Manpreet K. Aulakh
  ChemistrySelect.2023;[Epub]     CrossRef
• A multiparametric fluorescent visualization approach for detecting drug resistance in living cancer cells
  Zhilan Zhou, Ya Wang, Zhengtao Shao, Guixi Zhang, Hang Jiang, Yiyuan Tang, Zening Huang, Yingdi Zhu, Juan Li
  Talanta.2023; 259: 124564.     CrossRef
• Targeting MET: Discovery of Small Molecule Inhibitors as Non-Small Cell Lung Cancer Therapy
  Chaofan Wang, Xiaoyun Lu
  Journal of Medicinal Chemistry.2023; 66(12): 7670.     CrossRef
• Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer
  Hugo Arasanz, Luisa Chocarro, Leticia Fernández-Rubio, Ester Blanco, Ana Bocanegra, Miriam Echaide, Ibone Labiano, Ana Elsa Huerta, Maria Alsina, Ruth Vera, David Escors, Grazyna Kochan
  International Journal of Molecular Sciences.2023; 24(12): 9855.     CrossRef
• An Observatory for the MET Oncogene: A Guide for Targeted Therapies
  Dogus M. Altintas, Paolo M. Comoglio
  Cancers.2023; 15(18): 4672.     CrossRef
• Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer
  Zhen-Xi Niu, Ya-Tao Wang, Nan Lu, Jin-Feng Sun, Peng Nie, Piet Herdewijn
  European Journal of Medicinal Chemistry.2023; 261: 115868.     CrossRef
• Epigenetic regulation in lung cancer
  Shahin Ramazi, Maedeh Dadzadi, Zahra Sahafnejad, Abdollah Allahverdi
  MedComm.2023;[Epub]     CrossRef
• SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status
  Brianna R. Daley, Heidi M. Vieira, Chaitra Rao, Jacob M. Hughes, Zaria M. Beckley, Dianna H. Huisman, Deepan Chatterjee, Nancy E. Sealover, Katherine Cox, James W. Askew, Robert A. Svoboda, Kurt W. Fisher, Robert E. Lewis, Robert L. Kortum
  Proceedings of the National Academy of Sciences.2023;[Epub]     CrossRef
• KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block
  Juan Esteban Garcia-Robledo, Rafael Rosell, Alejandro Ruíz-Patiño, Carolina Sotelo, Oscar Arrieta, Lucia Zatarain-Barrón, Camila Ordoñez, Elvira Jaller, Leonardo Rojas, Alessandro Russo, Diego de Miguel-Pérez, Christian Rolfo, Andrés F. Cardona
  Therapeutic Advances in Respiratory Disease.2022;[Epub]     CrossRef
• MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis
  Daniel Lu, Amy Nagelberg, Justine LM Chow, Yankuan T Chen, Quentin Michalchuk, Romel Somwar, William W. Lockwood
  Cancers.2022; 14(6): 1378.     CrossRef
• hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
  Ilaria Martinelli, Chiara Modica, Cristina Chiriaco, Cristina Basilico, James M. Hughes, Simona Corso, Silvia Giordano, Paolo M. Comoglio, Elisa Vigna
  Journal of Experimental & Clinical Cancer Research.2022;[Epub]     CrossRef
• PIK3CAMutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
  Aryana R. Rasti, Amy Guimaraes-Young, Farrah Datko, Virginia F. Borges, Dara L. Aisner, Elena Shagisultanova
  JCO Precision Oncology.2022;[Epub]     CrossRef
• Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
  Yang Yang, Shuo Li, Yujiao Wang, Yi Zhao, Qiu Li
  Signal Transduction and Targeted Therapy.2022;[Epub]     CrossRef
• MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies
  Solange Rivas, Arnaldo Marín, Suraj Samtani, Evelin González-Feliú, Ricardo Armisén
  International Journal of Molecular Sciences.2022; 23(22): 13898.     CrossRef
• Advances in the Lung Cancer Immunotherapy Approaches
  Hafiza Padinharayil, Reema Rose Alappat, Liji Maria Joy, Kavya V. Anilkumar, Cornelia M. Wilson, Alex George, Abilash Valsala Gopalakrishnan, Harishkumar Madhyastha, Thiyagarajan Ramesh, Ezhaveni Sathiyamoorthi, Jintae Lee, Raja Ganesan
  Vaccines.2022; 10(11): 1963.     CrossRef
• A comprehensive review on the biological interest of quinoline and its derivatives
  Basavarajaiah Suliphuldevara Matada, Raviraj Pattanashettar, Nagesh Gunavanthrao Yernale
  Bioorganic & Medicinal Chemistry.2021; 32: 115973.     CrossRef
• Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer
  Fatemeh Moosavi, Elisa Giovannetti, Godefridus J. Peters, Omidreza Firuzi
  Critical Reviews in Oncology/Hematology.2021; 160: 103234.     CrossRef
• Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
  Aaron Tan, Tracy J Loh, Xue Lin Kwang, Gek San Tan, Kiat Hon Lim, Daniel SW Tan
  Lung Cancer: Targets and Therapy.2021; Volume 12: 11.     CrossRef
• Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors
  Qing Tang, Alex M. Aronov, David D. Deininger, Simon Giroux, David J. Lauffer, Pan Li, Jianglin Liang, Kira McGinty, Steven Ronkin, Rebecca Swett, Nathan Waal, Diane Boucher, Pamella J. Ford, Cameron S. Moody
  ACS Medicinal Chemistry Letters.2021; 12(6): 955.     CrossRef
• Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Proteolysis-Targeting Chimeras: The Pharmacology of Cutting-Edge Lung Cancer Therapies
  Jennifer W. Carlisle, R. Donald Harvey
  American Society of Clinical Oncology Educational Book.2021; (41): e286.     CrossRef
• Response to crizotinib in a patient with MET‐amplified hepatocellular carcinoma
  Qinglian Chen, Chunfeng Xie, Kunliang Feng, Haijun Huang, Chengming Xiong, Tengjiao Lin, Wenjing Wang, Mian Xu, Xianwei Yang, Chong Zhong
  Hepatology Research.2021; 51(11): 1164.     CrossRef
• New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications
  Thais Cristina Mendonça Nogueira, Marcus Vinicius Nora de Souza
  Bioorganic & Medicinal Chemistry.2021; 46: 116340.     CrossRef
• Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer
  Alex Martinez-Marti, Enriqueta Felip, Francesco Mattia Mancuso, Ginevra Caratú, Judit Matito, Paolo Nuciforo, Irene Sansano, Nely Diaz-Mejia, Susana Cedrés, Ana Callejo, Patricia Iranzo, Nuria Pardo, Josep Maria Miquel, Alejandro Navarro, Ana Vivancos, Mi
  British Journal of Cancer.2021; 125(11): 1561.     CrossRef
• A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
  John O. DaSilva, Katie Yang, Oliver Surriga, Thomas Nittoli, Arthur Kunz, Matthew C. Franklin, Frank J. Delfino, Shu Mao, Feng Zhao, Jason T. Giurleo, Marcus P. Kelly, Sosina Makonnen, Carlos Hickey, Pamela Krueger, Randi Foster, Zhaoyuan Chen, Marc W. Re
  Molecular Cancer Therapeutics.2021; 20(10): 1966.     CrossRef
• Development and full validation of an LC–MS/MS methodology to quantify capmatinib (INC280) following intragastric administration to rats
  Xiaoguang Fan, Guanghu Yang, Wenjuan Cui, Qin Liu, Zhaolong Zhang, Zhikun Zhang
  Biomedical Chromatography.2020;[Epub]     CrossRef
• A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients
  Giorgio Scagliotti, Denis Moro-Sibilot, Jens Kollmeier, Adolfo Favaretto, Eun Kyung Cho, Heidrun Grosch, Martin Kimmich, Nicolas Girard, Chun-Ming Tsai, Te-Chun Hsia, Matteo Brighenti, Christian Schumann, Xuejing Aimee Wang, Sameera R. Wijayawardana, Aaro
  Journal of Thoracic Oncology.2020; 15(1): 80.     CrossRef
• Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer
  Roberto Ruiz-Cordero, Walter Patrick Devine
  Surgical Pathology Clinics.2020; 13(1): 17.     CrossRef
• Meta-analysis of functional expression and mutational analysis of c-Met in various cancers
  Murugesan Sivakumar, Murugesan Jayakumar, Palaniappan Seedevi, Palaniappan Sivasankar, Muthu Ravikumar, Sundharaiyya Surendar, Tamilselvi Murugan, Shahid S. Siddiqui, Sivakumar Loganathan
  Current Problems in Cancer.2020; 44(4): 100515.     CrossRef
• Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement
  Xing Huang, Enliang Li, Hang Shen, Xun Wang, Tianyu Tang, Xiaozhen Zhang, Jian Xu, Zengwei Tang, Chengxiang Guo, Xueli Bai, Tingbo Liang
  Frontiers in Cell and Developmental Biology.2020;[Epub]     CrossRef
• Statins use and its impact in EGFR‐TKIs resistance to prolong the survival of lung cancer patients: A Cancer registry cohort study in Taiwan
  Phung‐Anh Nguyen, Chih‐Cheng Chang, Cooper J. Galvin, Yao‐Chin Wang, Soo Yeon An, Chih‐Wei Huang, Yu‐Hsiang Wang, Min‐Huei Hsu, Yu‐Chuan (Jack) Li, Hsuan‐Chia Yang
  Cancer Science.2020; 111(8): 2965.     CrossRef
• A Single-Step, High-Dose Selection Scheme Reveals Distinct Mechanisms of Acquired Resistance to Oncogenic Kinase Inhibition in Cancer Cells
  Kenneth J. Finn, Scott E. Martin, Jeff Settleman
  Cancer Research.2020; 80(1): 79.     CrossRef
• Emerging therapies for non-small cell lung cancer
  Chao Zhang, Natasha B. Leighl, Yi-Long Wu, Wen-Zhao Zhong
  Journal of Hematology & Oncology.2019;[Epub]     CrossRef
• Capmatinib for the treatment of non-small cell lung cancer
  Johan Filip Vansteenkiste, Charlotte Van De Kerkhove, Els Wauters, Pierre Van Mol
  Expert Review of Anticancer Therapy.2019; 19(8): 659.     CrossRef
• Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement
  Ji-Hyun Kwon, Kui-Jin Kim, Ji Hea Sung, Koung Jin Suh, Ji Yun Lee, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Soyeon Kim, Sung-Soo Yoon, Jong Seok Lee
  Cells.2019; 8(12): 1538.     CrossRef
• DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
  Yang‐ling Li, Ke Ding, Xiu Hu, Lin‐wen Wu, Dong‐mei Zhou, Ming‐jun Rao, Neng‐ming Lin, Chong Zhang
  Journal of Cellular and Molecular Medicine.2019; 23(11): 7427.     CrossRef
• MiR-1246 Promotes Metastasis and Invasion of A549 cells by Targeting GSK-3β‒Mediated Wnt/β-Catenin Pathway
  Fan Yang, Hairong Xiong, Li Duan, Qian Li, Xin Li, Yongqin Zhou
  Cancer Research and Treatment.2019; 51(4): 1420.     CrossRef

Citations

Citations to this article as recorded by  

• IL-1β in Neoplastic Disease and the Role of Its Tumor-Derived Form in the Progression and Treatment of Metastatic Prostate Cancer
  Yetunde Oyende, Luke J. Taus, Alessandro Fatatis
  Cancers.2025; 17(2): 290.     CrossRef
• Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
  Daniel S.W. Tan, Enriqueta Felip, Gilberto de Castro, Benjamin J. Solomon, Alastair Greystoke, Byoung Chul Cho, Manuel Cobo, Tae Min Kim, Sandip Ganguly, Enric Carcereny, Luis Paz-Ares, Jaafar Bennouna, Marina Chiara Garassino, Michael Schenker, Sang-We K
  Journal of Clinical Oncology.2024; 42(2): 192.     CrossRef
• Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 t
  Luis Paz-Ares, Yasushi Goto, Darren Wan-Teck Lim, Balazs Halmos, Byoung Chul Cho, Manuel Cobo, José Luis González Larriba, Caicun Zhou, Ingel Demedts, Akin Atmaca, Sofia Baka, Bijoyesh Mookerjee, Socorro Portella, Zewen Zhu, Jincheng Wu, David Demanse, Bh
  Lung Cancer.2024; 189: 107451.     CrossRef
• Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer
  Wanda Marini, Brooke E. Wilson, Michael Reedijk
  DNA and Cell Biology.2023; 42(2): 73.     CrossRef
• IL-1β is involved in docetaxel chemoresistance by regulating the formation of polyploid giant cancer cells in non-small cell lung cancer
  Song Zhao, Sining Xing, Lili Wang, Mingyue Ouyang, Shuo Liu, Lingyan Sun, Huiying Yu
  Scientific Reports.2023;[Epub]     CrossRef
• Prognostic Implications of Pyroptosis-Related Gene Signatures in Lung Squamous Cell Carcinoma
  Tingting Li, Huanqing Liu, Chunsheng Dong, Jun Lyu
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses
  Mélanie Bruchard, Mannon Geindreau, Anaïs Perrichet, Caroline Truntzer, Elise Ballot, Romain Boidot, Cindy Racoeur, Emilie Barsac, Fanny Chalmin, Christophe Hibos, Thomas Baranek, Christophe Paget, Bernhard Ryffel, Cédric Rébé, Catherine Paul, Frédérique
  Nature Immunology.2022; 23(2): 262.     CrossRef
• Targeting interleukin-1β and inflammation in lung cancer
  Jun Zhang, Nirmal Veeramachaneni
  Biomarker Research.2022;[Epub]     CrossRef
• Immunohistochemical Detection of Pro-Inflammatory and Anti-Inflammatory Interleukins in the Lungs of Sheep with Jaagsiekte
  Emin KARAKURT, Enver BEYTUT, Serpil DAĞ, Hilmi NUHOĞLU, Ayfer YILDIZ, Emre KURTBAŞ
  Turkish Journal of Veterinary Research.2022; 6(1): 9.     CrossRef
• Implications of Hyperoxia over the Tumor Microenvironment: An Overview Highlighting the Importance of the Immune System
  Ana Belén Herrera-Campos, Esteban Zamudio-Martinez, Daniel Delgado-Bellido, Mónica Fernández-Cortés, Luis M. Montuenga, F. Javier Oliver, Angel Garcia-Diaz
  Cancers.2022; 14(11): 2740.     CrossRef
• Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology
  Mark P. Lythgoe, Vinay Prasad
  British Journal of Cancer.2022; 127(5): 785.     CrossRef
• Promotion of angiogenesis in vitro by Astragalus polysaccharide via activation of TLR4 signaling pathway
  Huiqing Qiu, Liyan Zhang, Xinqi He, Yusen Wei, Miaoran Wang, Bin Ma, Dailun Hu, Zhongli Shi
  Journal of Food Biochemistry.2022;[Epub]     CrossRef
• B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis
  Anqi Lin, Jianbo Fang, Quan Cheng, Zaoqu Liu, Peng Luo, Jian Zhang
  Journal of Inflammation Research.2022; Volume 15: 5541.     CrossRef
• Biological Rationale for Peripheral Blood Cell–Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer
  Giuseppe Luigi Banna, Alex Friedlaender, Marco Tagliamento, Veronica Mollica, Alessio Cortellini, Sara Elena Rebuzzi, Arsela Prelaj, Abdul Rafeh Naqash, Edouard Auclin, Lucia Garetto, Laura Mezquita, Alfredo Addeo
  Current Oncology Reports.2022; 24(12): 1851.     CrossRef
• IL-1β enhances cell viability and decreases 5-FU sensitivity in novel colon cancer cell lines derived from African American patients
  Marzia Spagnardi, Jenny Paredes, Jovanny Zabaleta, Jone Garai, Tiana Reyes, Laura A. Martello, Jennie L. Williams
  Frontiers in Oncology.2022;[Epub]     CrossRef
• Immune Resistance in Lung Adenocarcinoma
  Magda Spella, Georgios T. Stathopoulos
  Cancers.2021; 13(3): 384.     CrossRef
• The Role of Tumor Inflammatory Microenvironment in Lung Cancer
  Zhaofeng Tan, Haibin Xue, Yuli Sun, Chuanlong Zhang, Yonglei Song, Yuanfu Qi
  Frontiers in Pharmacology.2021;[Epub]     CrossRef
• Interleukin-1β and Cancer
  Cédric Rébé, François Ghiringhelli
  Cancers.2020; 12(7): 1791.     CrossRef
• Immune Cells Combined With NLRP3 Inflammasome Inhibitor Exert Better Antitumor Effect on Pancreatic Ductal Adenocarcinoma
  Hailiang Liu, Yong Xu, Kai Liang, Rong Liu
  Frontiers in Oncology.2020;[Epub]     CrossRef
• Identification of a novel subpopulation of Caspase-4 positive non-small cell lung Cancer patients
  Michela Terlizzi, Chiara Colarusso, Ilaria De Rosa, Pasquale Somma, Carlo Curcio, Rita P. Aquino, Luigi Panico, Rosario Salvi, Federica Zito Marino, Gerardo Botti, Aldo Pinto, Rosalinda Sorrentino
  Journal of Experimental & Clinical Cancer Research.2020;[Epub]     CrossRef
• A review of canakinumab and its therapeutic potential for non-small cell lung cancer
  Kara M. Schenk, Joshua E. Reuss, Karin Choquette, Alexander I. Spira
  Anti-Cancer Drugs.2019; 30(9): 879.     CrossRef
• Listeria monocytogenes Cancer Vaccines: Bridging Innate and Adaptive Immunity
  Zachary T. Morrow, Zachary M. Powers, John-Demian Sauer
  Current Clinical Microbiology Reports.2019; 6(4): 213.     CrossRef
• Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging
  Ahmed Salem, Hitesh Mistry, Alison Backen, Clare Hodgson, Pek Koh, Emma Dean, Lynsey Priest, Kate Haslett, Ioannis Trigonis, Alan Jackson, Marie-Claude Asselin, Caroline Dive, Andrew Renehan, Corinne Faivre-Finn, Fiona Blackhall
  Clinical Lung Cancer.2018; 19(3): 239.     CrossRef
• Elucidating the Role of CD84 and AHR in Modulation of LPS-Induced Cytokines Production by Cruciferous Vegetable-Derived Compounds Indole-3-Carbinol and 3,3′-Diindolylmethane
  Thomas Wang, Quynhchi Pham, Young Kim
  International Journal of Molecular Sciences.2018; 19(2): 339.     CrossRef
• IL‐1β promotes the nuclear translocaiton of S100A4 protein in gastric cancer cells MGC803 and the cell's stem‐like properties through PI3K pathway
  Aiwen Yu, Yu Wang, Yue Bian, Lisha Chen, Junfu Guo, Wei Shen, Danqi Chen, Shanshan Liu, Xiuju Sun
  Journal of Cellular Biochemistry.2018; 119(10): 8163.     CrossRef
• SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patients
  Camille Emprou, Pauline Le Van Quyen, Jérémie Jégu, Nathalie Prim, Noëlle Weingertner, Eric Guérin, Erwan Pencreach, Michèle Legrain, Anne‐Claire Voegeli, Charlotte Leduc, Bertrand Mennecier, Pierre‐Emmanuel Falcoz, Anne Olland, Nicolas Santelmo, Elisabet
  Cancer Medicine.2018; 7(7): 3278.     CrossRef
• RNA-Sequencing data supports the existence of novel VEGFA splicing events but not of VEGFAxxxb isoforms
  Stephen Bridgett, Margaret Dellett, David A. Simpson
  Scientific Reports.2017;[Epub]     CrossRef
• Cordycepin inhibits LPS-induced inflammatory responses by modulating NOD-Like Receptor Protein 3 inflammasome activation
  Jing Yang, Yun-zhou Li, Phillip B. Hylemon, Lu-yong Zhang, Hui-ping Zhou
  Biomedicine & Pharmacotherapy.2017; 95: 1777.     CrossRef
• Syndrome of Inappropriate Antidiuretic Hormone Secretion: A Poor Prognosis in Small-cell Lung Cancer
  Xu Wang, Min Liu, Lei Zhang, Kewei Ma
  Archives of Medical Research.2016; 47(1): 19.     CrossRef
• Prediction of survival and tumor recurrence in patients undergoing surgery for pancreatic neuroendocrine neoplasms
  Alexander Kaltenborn, Svenja Matzke, Moritz Kleine, Till Krech, Wolf Ramackers, Florian W. R. Vondran, Jürgen Klempnauer, Hüseyin Bektas, Harald Schrem
  Journal of Surgical Oncology.2016; 113(2): 194.     CrossRef
• Association of CT perfusion imaging with plasma levels of TGF-β1 and VEGF in patients with NSCLC
  Da-Wei Li, Bao-Zhong Wu, Yu-Sen Shi, Zhi-Qun Li, Xu-Dong Liu, Xiao-Hua Li
  Asian Pacific Journal of Tropical Medicine.2016; 9(2): 177.     CrossRef
• Promotion of a cancer-like phenotype, through chronic exposure to inflammatory cytokines and hypoxia in a bronchial epithelial cell line model
  Anne-Marie Baird, Steven G. Gray, Derek J. Richard, Kenneth J. O’Byrne
  Scientific Reports.2016;[Epub]     CrossRef
• Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity
  Kristian Hargadon
  Journal of Clinical Medicine.2016; 5(9): 76.     CrossRef
• Associations of Circulating Cytokines and Chemokines With Cancer Mortality in Men With Rheumatoid Arthritis
  Bryant R. England, Jeremy Sokolove, William H. Robinson, Geoffrey M. Thiele, Apar K. Ganti, Harlan Sayles, Kaleb Michaud, Liron Caplan, Lisa A. Davis, Grant W. Cannon, Brian Sauer, Namrata Singh, E. Blair Solow, Andreas M. Reimold, Gail S. Kerr, Pascale S
  Arthritis & Rheumatology.2016; 68(10): 2394.     CrossRef
• The inflammasome: an emerging therapeutic oncotarget for cancer prevention
  Wang Zhiyu, Neng Wang, Qi Wang, Cheng Peng, Jin Zhang, Pengxi Liu, Aihua Ou, Shaowen Zhong, Mario D. Cordero, Yi Lin
  Oncotarget.2016; 7(31): 50766.     CrossRef
• Elevated chronic inflammatory factors and myeloid‐derived suppressor cells indicate poor prognosis in advanced melanoma patients
  Huanhuan Jiang, Christoffer Gebhardt, Ludmila Umansky, Philipp Beckhove, Torsten J. Schulze, Jochen Utikal, Viktor Umansky
  International Journal of Cancer.2015; 136(10): 2352.     CrossRef
• The Clinical Research of Serum VEGF, TGF-β1, and Endostatin in Non-small Cell Lung Cancer
  Shu-Guang Liu, Shuang-Hu Yuan, Hui-Yong Wu, Jie Liu, Cheng-Suo Huang
  Cell Biochemistry and Biophysics.2015; 72(1): 165.     CrossRef
• Platelet VEGF and serum TGF-β1 levels predict chemotherapy response in non-small cell lung cancer patients
  Bao-Hong Fu, Zhan-Zhao Fu, Wei Meng, Tao Gu, Xiao-Dong Sun, Zhi Zhang
  Tumor Biology.2015; 36(8): 6477.     CrossRef
• Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy
  Morena Fasano, Carminia Maria Della Corte, Federica Papaccio, Fortunato Ciardiello, Floriana Morgillo
  Journal of Thoracic Oncology.2015; 10(8): 1133.     CrossRef
• The angiogenic responses induced by release of angiogenic proteins from tumor cell‐activated platelets are regulated by distinct molecular pathways
  Hongyan Wu, Fangtian Fan, Zhaoguo Liu, Feng Zhang, Yuping Liu, Zhonghong Wei, Cunsi Shen, Yuzhu Cao, Aiyun Wang, Yin Lu
  IUBMB Life.2015; 67(8): 626.     CrossRef
• Serum Calprotectin, CD26 and EGF to Establish a Panel for the Diagnosis of Lung Cancer
  Sonia Blanco-Prieto, Lorena Vázquez-Iglesias, Mar Rodríguez-Girondo, Leticia Barcia-Castro, Alberto Fernández-Villar, María Isabel Botana-Rial, Francisco Javier Rodríguez-Berrocal, María Páez de la Cadena, Rossella Rota
  PLOS ONE.2015; 10(5): e0127318.     CrossRef